Thomas Hovenic, MD
Infectious Disease · Reno, NVNPI 1073639761
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 153 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Cipla USA Inc. at 46.8% of the total. Reporting peaked in 2021 at $3,944 and has fallen 89.2% since, to $427 in 2025.
Across 153 payments — averaging $42.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cipla USA Inc.$3K
- AbbVie$1K
- Organogenesis Inc.$375
- Astellas Pharma US Inc$235
- Gilead$208
- Johnson & Johnson$178
- plus $1K from 24 others
What the payments were for
- Food & beverage$6,27696%
- Education$2404%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cipla USA Inc. | 5 | $3,049 |
| AbbVie(2 entities) | 65 | $1,457 |
| Organogenesis Inc. | 9 | $375 |
| Astellas Pharma US Inc | 7 | $235 |
| Gilead | 10 | $208 |
| Johnson & Johnson(2 entities) | 9 | $178 |
| Merck | 10 | $167 |
| La Jolla Pharmaceutical Company | 1 | $106 |
| Viiv Healthcare Company | 3 | $79 |
| Paratek Pharmaceuticals, Inc. | 4 | $72 |
| Sanofi | 4 | $71 |
| Tetraphase Pharmaceuticals, Inc. | 3 | $63 |
| Pfizer | 3 | $54 |
| Amgen | 2 | $40 |
| Biofrontera Inc. | 3 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $30 |
| Biotissue Holdings Inc. | 1 | $30 |
| Mimedx Group, Inc. | 1 | $28 |
| Theratechnologies Inc. | 1 | $25 |
| Polynovo North America LLC | 1 | $25 |
| Insmed, Inc. | 1 | $24 |
| United Therapeutics Corporation | 1 | $21 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $21 |
| Indivior Inc. | 1 | $19 |
| Vyera Pharmaceuticals, LLC | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Shire North American Group Inc | 1 | $15 |
| UCB, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,516 in reported general payments places this provider in the 75th percentile of 65 infectious disease providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 13 | $4,440 |
| Doxycycline Hyclate | 27 | $455 |
| Cephalexin | 13 | $354 |
| Doxycycline Monohydrate | 31 | $218 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 19 | $129 |
| Triamcinolone Acetonide | 16 | $111 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Reno
- Elaine YeeReno$8K
- Steven ParkerReno$6K
- Franklin MurphyReno$3K
- Raymond SwartsReno$873
- Andres Adrianza PachecoReno$840
- Samuel LeeReno$412
- Natalie CrawfordReno$204
- Michael ZouReno$156
- Christina BaileyReno$149
- Jasmine DhindsaReno$125
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.